March 15, 2010 — The US Food and Drug Administration (FDA) has approved a twice-yearly 22.5-mg formulation of triptorelin pamoate injection (Trelstar, Watson Pharmaceuticals, Inc) for the palliative ...
Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality ...
Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding ...
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release ...
HealthDay News — For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ...
Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback